BR112013031084A2 - meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas - Google Patents

meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas

Info

Publication number
BR112013031084A2
BR112013031084A2 BR112013031084A BR112013031084A BR112013031084A2 BR 112013031084 A2 BR112013031084 A2 BR 112013031084A2 BR 112013031084 A BR112013031084 A BR 112013031084A BR 112013031084 A BR112013031084 A BR 112013031084A BR 112013031084 A2 BR112013031084 A2 BR 112013031084A2
Authority
BR
Brazil
Prior art keywords
methods
hydrostatic pressure
tumor cells
high hydrostatic
dendritic cells
Prior art date
Application number
BR112013031084A
Other languages
English (en)
Other versions
BR112013031084B1 (pt
Inventor
Jirina Bartunková
Radek Spisek
Original Assignee
Sotio As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio As filed Critical Sotio As
Priority to BR122019026627-1A priority Critical patent/BR122019026627B1/pt
Publication of BR112013031084A2 publication Critical patent/BR112013031084A2/pt
Publication of BR112013031084B1 publication Critical patent/BR112013031084B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas". a presente invenção refere-se a composições para induzir uma resposta imune contra células tumorais compreendendo células tumorais que são transformadas em apoptóticas por tratamento com alta pressão hidrostática e células dendríticas, e métodos para produzir tais composições. 19922436v1
BR112013031084-7A 2011-07-05 2012-07-04 composição farmacêutica para induzir uma resposta imune contra células tumorais e seu método de preparação BR112013031084B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019026627-1A BR122019026627B1 (pt) 2011-07-05 2012-07-04 uso de ce´lulas dendri´ticas imaturas carregadas com ce´lulas tumorais apopto´ticas para a preparac¸a~o de uma vacina tumoral

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161504387P 2011-07-05 2011-07-05
US61/504,387 2011-07-05
EP11172622.0 2011-07-05
EP11172622A EP2543386A1 (en) 2011-07-05 2011-07-05 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
PCT/EP2012/062950 WO2013004708A1 (en) 2011-07-05 2012-07-04 Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Publications (2)

Publication Number Publication Date
BR112013031084A2 true BR112013031084A2 (pt) 2016-11-29
BR112013031084B1 BR112013031084B1 (pt) 2021-01-12

Family

ID=44359435

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013031084-7A BR112013031084B1 (pt) 2011-07-05 2012-07-04 composição farmacêutica para induzir uma resposta imune contra células tumorais e seu método de preparação
BR122019026627-1A BR122019026627B1 (pt) 2011-07-05 2012-07-04 uso de ce´lulas dendri´ticas imaturas carregadas com ce´lulas tumorais apopto´ticas para a preparac¸a~o de uma vacina tumoral

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019026627-1A BR122019026627B1 (pt) 2011-07-05 2012-07-04 uso de ce´lulas dendri´ticas imaturas carregadas com ce´lulas tumorais apopto´ticas para a preparac¸a~o de uma vacina tumoral

Country Status (20)

Country Link
US (1) US20140086957A1 (pt)
EP (2) EP2543386A1 (pt)
JP (1) JP5986196B2 (pt)
KR (1) KR102035873B1 (pt)
CN (3) CN102861103A (pt)
AU (2) AU2012280322B2 (pt)
BR (2) BR112013031084B1 (pt)
CA (1) CA2833946A1 (pt)
DK (1) DK2691110T3 (pt)
EA (1) EA030061B1 (pt)
ES (1) ES2525759T3 (pt)
PL (1) PL2691110T3 (pt)
PT (1) PT2691110E (pt)
RS (1) RS53713B1 (pt)
RU (1) RU2012127685A (pt)
SG (1) SG194201A1 (pt)
SI (1) SI2691110T1 (pt)
SM (1) SMT201400188B (pt)
UA (1) UA111738C2 (pt)
WO (1) WO2013004708A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011438A1 (en) 2011-07-05 2013-01-10 SOTIO a.s. Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
CN104258384B (zh) * 2014-09-29 2017-05-03 北京时合生物科技有限公司 一种基于树突状细胞的特异性肿瘤疫苗的制备方法
CN107921063A (zh) * 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN106244543A (zh) * 2016-07-29 2016-12-21 北京时合生物科技有限公司 一种pbmc体外诱导分化成为树突状细胞的方法
CN110392574A (zh) * 2017-02-17 2019-10-29 艾维塔生物医学公司 使用经修饰的肿瘤细胞和经修饰的树突细胞增强肿瘤免疫原性的方法和用于自体癌症免疫治疗产品的组合物
WO2019101110A1 (zh) * 2017-11-21 2019-05-31 中国科学院上海药物研究所 天花粉蛋白用于致敏和/激活树突状细胞中的应用
EA202091743A1 (ru) 2018-01-25 2020-12-08 Сотио А.С. Вакцинация дендритными клетками параллельно с химиотерапией
EA202091745A1 (ru) * 2018-01-25 2020-12-14 Сотио А.С. Вакцинация дендритными клетками после химиотерапии
WO2020187975A1 (en) 2019-03-19 2020-09-24 SOTIO a.s. Patient selection for treatment with dendritic cell vaccination
JP7340240B2 (ja) * 2019-08-26 2023-09-07 学校法人関西医科大学 細胞又は組織にアポトーシスを誘導する方法
WO2022171792A1 (en) 2021-02-12 2022-08-18 Sctbio A.S. Patient selection for treatment with dendritic cell vaccination
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
CN114807229A (zh) * 2022-05-27 2022-07-29 中国科学院长春应用化学研究所 细胞膜、纳米疫苗及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602709B1 (en) * 1998-02-20 2003-08-05 The Rockefeller University Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
CN101052709B (zh) 2004-10-25 2012-06-27 贝勒研究院 装载热激黑素瘤细胞体的树突细胞
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
KR100647847B1 (ko) 2005-05-27 2006-11-23 크레아젠 주식회사 인간 전립선암 동물모델 및 이를 이용한 수지상세포-유래전립선암 면역치료제의 예방 및 치료 효능을 분석하는 방법

Also Published As

Publication number Publication date
RS53713B1 (en) 2015-04-30
JP2014520780A (ja) 2014-08-25
EA030061B1 (ru) 2018-06-29
BR112013031084B1 (pt) 2021-01-12
NZ618000A (en) 2014-12-24
CN103648524B (zh) 2016-08-17
CN103648524A (zh) 2014-03-19
CN102861103A (zh) 2013-01-09
DK2691110T3 (en) 2014-11-17
PL2691110T3 (pl) 2015-03-31
AU2012280322B2 (en) 2016-07-21
KR20140040734A (ko) 2014-04-03
CA2833946A1 (en) 2013-01-10
SG194201A1 (en) 2013-11-29
US20140086957A1 (en) 2014-03-27
EA201301089A1 (ru) 2014-05-30
SI2691110T1 (sl) 2015-01-30
EP2691110B1 (en) 2014-10-29
RU2012127685A (ru) 2014-01-20
BR122019026627B1 (pt) 2021-01-12
KR102035873B1 (ko) 2019-10-23
EP2543386A1 (en) 2013-01-09
CN109125347A (zh) 2019-01-04
WO2013004708A1 (en) 2013-01-10
ES2525759T3 (es) 2014-12-30
JP5986196B2 (ja) 2016-09-06
AU2016234915A1 (en) 2016-10-20
SMT201400188B (it) 2015-03-05
EP2691110A1 (en) 2014-02-05
UA111738C2 (uk) 2016-06-10
AU2016234915B2 (en) 2017-08-31
PT2691110E (pt) 2014-12-22

Similar Documents

Publication Publication Date Title
BR112013031084A2 (pt) meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
CL2017001968A1 (es) Ácidos 3-alquil-4-amido-bicíclico [4.5.0] hidroxámico como inhibidores de hdac
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
CO6612271A2 (es) Anticuerpos anti-cd40
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2019010735A (es) Sistemas y metodos para la produccion dirigida de una proteina terapeutica dentro de una celula objetivo.
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MX2015012034A (es) El péptido mots3 derivado de mitocondrias regula el metabolismo y supervivencia celular.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112014003477A2 (pt) composições imunoterapêuticas de levedura-muc1 e usos das mesmas
MY180613A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
EA201690964A1 (ru) Композиции и способы для уменьшения серьезных неблагоприятных сердечно-сосудистых явлений
DK2252322T3 (da) Vaccinesammensætninger
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MX365403B (es) Peptidos y metodos para usarlos.
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
CY1115803T1 (el) Μεσα και μεθοδοι ενεργης κυτταρικης ανοσοθεραπειας εναντι καρκινου χρησιμοποιωντας κυτταρα ογκου θανατωμενα υπο μεγαλη υδροστατικη πιεση και δενδριτικα κυτταρα

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/07/2012, OBSERVADAS AS CONDICOES LEGAIS.